Combination MTD and metronomic chemotherapy – a better way to organ preservation and remission in advanced HNSCC?

Michael Schedler & Dimitre Christoph
Treatment of advanced HNSCC still lacks a gold standard. Variable MTD (maximal tolerated dose) regimens have been in use for UICC stage III and IV HNSCC since 1985, and finding the right regimen may get confusing. Cisplatin (CDDP) based regimens are well established as well in induction (neoadjuvant)[for full text, please go to the a.m. URL]